Sandra Shpilberg, MBA

Ms. Sandra Shpilberg is the Senior Director of PKU Marketing at BioMarin Pharmaceutical Inc. She joined BioMarin in April 2005 and led the development of the company’s marketing and commercial capabilities to launch products. Ms. Shpilberg led the launch of Kuvan, a first-to-market medicine for PKU, a genetic condition.

Ms. Shpilberg also led the company’s entry into social media as an effective community-building and marketing tool. In 2006, she launched PKU.com, a social networking site for patients with PKU. Since then social media efforts have been augmented. Ms. Shpilberg received the Gold Award from Medical Marketing & Media for Best Interactive Initiative for Consumers for the work on the PKU National Awareness Month Facebook Page.

Prior to BioMarin, Ms. Shpilberg was involved in the marketing of the blockbuster drug Remicade at Centocor, a Johnson & Johnson biotechnology company.

Ms. Shpilberg received her MBA in Marketing and Entrepreneurial Management at The Wharton School, at the University of Pennsylvania.